% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Kischkel:130831,
      author       = {F. C. Kischkel and C. Meyer and J. Eich and M. Nassir and
                      M. Mentze and I. Braicu and A. Kopp-Schneider$^*$ and J.
                      Sehouli},
      title        = {{P}rediction of clinical response to drugs in ovarian
                      cancer using the chemotherapy resistance test ({CTR}-test).},
      journal      = {Journal of ovarian research},
      volume       = {10},
      number       = {1},
      issn         = {1757-2215},
      address      = {London},
      publisher    = {BioMed Central},
      reportid     = {DKFZ-2017-05909},
      pages        = {72},
      year         = {2017},
      abstract     = {In order to validate if the test result of the Chemotherapy
                      Resistance Test (CTR-Test) is able to predict the
                      resistances or sensitivities of tumors in ovarian cancer
                      patients to drugs, the CTR-Test result and the corresponding
                      clinical response of individual patients were correlated
                      retrospectively. Results were compared to previous recorded
                      correlations.The CTR-Test was performed on tumor samples
                      from 52 ovarian cancer patients for specific
                      chemotherapeutic drugs. Patients were treated with
                      monotherapies or drug combinations. Resistances were
                      classified as extreme (ER), medium (MR) or slight (SR)
                      resistance in the CTR-Test. Combination treatment
                      resistances were transformed by a scoring system into these
                      classifications.Accurate sensitivity prediction was
                      accomplished in $79\%$ of the cases and accurate prediction
                      of resistance in $100\%$ of the cases in the total data set.
                      The data set of single agent treatment and drug combination
                      treatment were analyzed individually. Single agent treatment
                      lead to an accurate sensitivity in $44\%$ of the cases and
                      the drug combination to $95\%$ accuracy. The detection of
                      resistances was in both cases to $100\%$ correct. ROC curve
                      analysis indicates that the CTR-Test result correlates with
                      the clinical response, at least for the combination
                      chemotherapy. Those values are similar or better than the
                      values from a publication from 1990.Chemotherapy resistance
                      testing in vitro via the CTR-Test is able to accurately
                      detect resistances in ovarian cancer patients. These numbers
                      confirm and even exceed results published in 1990. Better
                      sensitivity detection might be caused by a higher percentage
                      of drug combinations tested in 2012 compared to 1990. Our
                      study confirms the functionality of the CTR-Test to plan an
                      efficient chemotherapeutic treatment for ovarian cancer
                      patients.},
      cin          = {C060},
      ddc          = {610},
      cid          = {I:(DE-He78)C060-20160331},
      pnm          = {313 - Cancer risk factors and prevention (POF3-313)},
      pid          = {G:(DE-HGF)POF3-313},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:29078793},
      pmc          = {pmc:PMC5658930},
      doi          = {10.1186/s13048-017-0365-9},
      url          = {https://inrepo02.dkfz.de/record/130831},
}